223 related articles for article (PubMed ID: 18378389)
21. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
[TBL] [Abstract][Full Text] [Related]
23. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.
Albers HM; Dong A; van Meeteren LA; Egan DA; Sunkara M; van Tilburg EW; Schuurman K; van Tellingen O; Morris AJ; Smyth SS; Moolenaar WH; Ovaa H
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7257-62. PubMed ID: 20360563
[TBL] [Abstract][Full Text] [Related]
24. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents.
Parrill AL; Baker DL
Anticancer Agents Med Chem; 2008 Dec; 8(8):917-23. PubMed ID: 19075574
[TBL] [Abstract][Full Text] [Related]
25. Measurement of autotaxin/lysophospholipase D activity.
Morris AJ; Smyth SS
Methods Enzymol; 2007; 434():89-104. PubMed ID: 17954243
[TBL] [Abstract][Full Text] [Related]
26. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors.
Xu X; Yang G; Zhang H; Prestwich GD
Prostaglandins Other Lipid Mediat; 2009 Sep; 89(3-4):140-6. PubMed ID: 19682598
[TBL] [Abstract][Full Text] [Related]
27. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
[TBL] [Abstract][Full Text] [Related]
28. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
[TBL] [Abstract][Full Text] [Related]
29. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts.
Parrill AL; Baker DL
Expert Opin Ther Pat; 2010 Dec; 20(12):1619-25. PubMed ID: 21047298
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.
Gupte R; Siddam A; Lu Y; Li W; Fujiwara Y; Panupinthu N; Pham TC; Baker DL; Parrill AL; Gotoh M; Murakami-Murofushi K; Kobayashi S; Mills GB; Tigyi G; Miller DD
Bioorg Med Chem Lett; 2010 Dec; 20(24):7525-8. PubMed ID: 21051230
[TBL] [Abstract][Full Text] [Related]
31. Autotaxin: a protein with two faces.
Tania M; Khan MA; Zhang H; Li J; Song Y
Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
[TBL] [Abstract][Full Text] [Related]
32. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
33. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
Zhang R; Wang J; Ma S; Huang Z; Zhang G
BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
[TBL] [Abstract][Full Text] [Related]
34. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain.
Inoue M; Ma L; Aoki J; Chun J; Ueda H
Mol Pain; 2008 Feb; 4():6. PubMed ID: 18261210
[TBL] [Abstract][Full Text] [Related]
35. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
Ptaszynska MM; Pendrak ML; Stracke ML; Roberts DD
Mol Cancer Res; 2010 Mar; 8(3):309-21. PubMed ID: 20197381
[TBL] [Abstract][Full Text] [Related]
36. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
37. Discovery and optimization of boronic acid based inhibitors of autotaxin.
Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
[TBL] [Abstract][Full Text] [Related]
38. Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties.
Yuelling LM; Fuss B
Biochim Biophys Acta; 2008 Sep; 1781(9):525-30. PubMed ID: 18485925
[TBL] [Abstract][Full Text] [Related]
39. ATX-LPA receptor axis in inflammation and cancer.
Liu S; Murph M; Panupinthu N; Mills GB
Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
[TBL] [Abstract][Full Text] [Related]
40. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
Baker DL; Fujiwara Y; Pigg KR; Tsukahara R; Kobayashi S; Murofushi H; Uchiyama A; Murakami-Murofushi K; Koh E; Bandle RW; Byun HS; Bittman R; Fan D; Murph M; Mills GB; Tigyi G
J Biol Chem; 2006 Aug; 281(32):22786-93. PubMed ID: 16782709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
